

Susana M Campos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10016401/publications.pdf>

Version: 2024-02-01

27
papers

1,312
citations

567144

15
h-index

580701

25
g-index

27
all docs

27
docs citations

27
times ranked

1443
citing authors

#	ARTICLE	IF	CITATIONS
1	Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5601-5606.	0.8	285
2	Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 497-504.	2.0	156
3	Multicenter, Randomized Phase II Trial of Oral CI-1033 for Previously Treated Advanced Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 5597-5604.	0.8	115
4	Role of pegylated liposomal doxorubicin in ovarian cancer. <i>Gynecologic Oncology</i> , 2005, 96, 10-18.	0.6	99
5	Phase II Study of Carboplatin, Paclitaxel, and Bevacizumab With Maintenance Bevacizumab As First-Line Chemotherapy for Advanced Malignant Ovarian Tumors. <i>Journal of Clinical Oncology</i> , 2010, 28, 154-159.	0.8	96
6	Aromatase Inhibitors for Breast Cancer in Postmenopausal Women. <i>Oncologist</i> , 2004, 9, 126-136.	1.9	90
7	Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1154-1164.e12.	1.5	88
8	Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1531-1539.	0.8	88
9	A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. <i>Gynecologic Oncology</i> , 2013, 128, 215-220.	0.6	46
10	A Current Review of Targeted Therapeutics for Ovarian Cancer. <i>Journal of Oncology</i> , 2010, 2010, 1-11.	0.6	45
11	Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial. <i>Gynecologic Oncology</i> , 2020, 159, 72-78.	0.6	41
12	Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer. <i>Gynecologic Oncology</i> , 2019, 154, 95-101.	0.6	29
13	The impact of anemia and its treatment on patients with gynecologic malignancies. <i>Seminars in Oncology</i> , 2002, 29, 7-12.	0.8	27
14	Hormonal Therapy in Postmenopausal Women with Breast Cancer. <i>Oncology</i> , 2003, 64, 289-299.	0.9	22
15	Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer. <i>Gynecologic Oncology</i> , 2019, 153, 471-478.	0.6	18
16	Antimitotic Inhibitors. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 607-628.	0.9	14
17	Vulvar Yolk Sac Tumors Are Somaticallly Derived SMARCB1 (INI-1)-Deficient Neoplasms. <i>American Journal of Surgical Pathology</i> , 2022, 46, 169-178.	2.1	12
18	Young Women Diagnosed with Early-Stage Ovarian Cancer or Borderline Malignancy of the Ovary: A Focus on Fertility and Sexual Function. <i>Journal of Psychosocial Oncology</i> , 2012, 30, 387-401.	0.6	10

#	ARTICLE	IF	CITATIONS
19	Anti-Epidermal Growth Factor Receptor Strategies for Advanced Breast Cancer. <i>Cancer Investigation</i> , 2008, 26, 757-768.	0.6	9
20	Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer. <i>International Journal of Clinical Oncology</i> , 2010, 15, 390-398.	1.0	6
21	Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors. <i>Gynecologic Oncology</i> , 2021, 161, 581-586.	0.6	5
22	Evolving treatment approaches for early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2005, 89, S1-S7.	1.1	3
23	Surveillance Imaging in Patients With Endometrial Cancer in First Remission. <i>Current Problems in Diagnostic Radiology</i> , 2018, 47, 311-316.	0.6	3
24	Mucinous differentiation does not impact stage or risk of recurrence among patients with grade 1, endometrioid type, endometrial carcinoma. <i>Gynecologic Oncology</i> , 2014, 135, 54-57.	0.6	2
25	Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. <i>Cancer</i> , 2016, 122, 3297-3306.	2.0	2
26	A phase I study of AZD2171 and Temsirolimus in patients with advanced gynecological malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 423-430.	1.1	1
27	Next-Generation Sequencing in the Diagnosis of Metastatic Lesions: Reclassification of a Glioblastoma as an Endometrial Cancer Metastasis to the Brain. <i>Oncologist</i> , 2021, 26, e2102-e2109.	1.9	0